WO1996003425A1 - Process for folding of proteins like recombinant hirudin or epidermal growth factor - Google Patents

Process for folding of proteins like recombinant hirudin or epidermal growth factor Download PDF

Info

Publication number
WO1996003425A1
WO1996003425A1 PCT/EP1995/002720 EP9502720W WO9603425A1 WO 1996003425 A1 WO1996003425 A1 WO 1996003425A1 EP 9502720 W EP9502720 W EP 9502720W WO 9603425 A1 WO9603425 A1 WO 9603425A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
process according
proteins
hirudin
concentration
Prior art date
Application number
PCT/EP1995/002720
Other languages
French (fr)
Inventor
Jui Yoa Chang
Original Assignee
Ciba-Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba-Geigy Ag filed Critical Ciba-Geigy Ag
Priority to AU31097/95A priority Critical patent/AU3109795A/en
Priority to JP8505402A priority patent/JPH11505507A/en
Priority to MX9700658A priority patent/MX9700658A/en
Priority to EP95926859A priority patent/EP0804461A1/en
Publication of WO1996003425A1 publication Critical patent/WO1996003425A1/en
Priority to NO970081A priority patent/NO970081D0/en
Priority to FI970230A priority patent/FI970230A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a process for the preparation of a biologically active and correctly folded protein in the presence of a denaturing agent.
  • CSF-1 colony stimulating factor-1
  • the procedures described involve the steps of initial solubilization of CSF-1 monomers isolated from inclusion bodies under reducing conditions in a chaotropic environment comprising urea or guanidine hydrochloride, refolding which is achieved by stepwise dilution of the chaotropic agents, and final oxidation of the refolded molecule in the presence of a redox-system.
  • IL-2 interieukin-2
  • IL-2 isolated from retractile bodies is denatured under reducing conditions with 6M guanidine hydrochloride, the soluble IL-2 is oxidized by a controlled oxidation in the presence of Cu 2+ ions, and the oxidized IL-2 refolded by reducing the concentration of the denaturant in the solution.
  • Interieukin-2 and interferon- ⁇ have been refolded using SDS for solubilization and Cu 2+ ions as oxidation promoters of the fully reduced protein (US-A-4572798).
  • the process for isolating recombinant retractile proteins as described in US-A-4620948 involves strong denaturing agents to solubilize the proteins, reducing conditions to facilitate correct folding and denaturant replacement in presence of air or other oxidizing agents to reform the disulfide bonds.
  • a method for renaturing unfolded proteins including cytochrome c, ovalbumin and trypsin inhibitor by reversibly binding of the denatured protein to a solid matrix and stepwise renaturing it by diluting the denaturant is disclosed in WO 86/5809.
  • the foregoing references are merely representative of a huge amount of literature dealing with the refolding of non-native proteins derived from different sources.
  • Guanidine hydrochloride (GdmCI) and urea are the best known denaturants for unfolding and inactivating proteins. Although the mechanism of their actions remains to be fully understood, it is generally evident that they disrupt the non-covalent interactions which stabilize the native conformation. The detrimental effect of GdmCI and urea has also been illustrated during the folding of proteins, which usually leads to the formation of inactive, scrambled species (Haber and Anfinsen, J. Biol. Chem. (1962), 237, 1839-1844; Weissman and Kim Science (1991 ), 253, 1386-1393). On the other hand, denaturants are potent agents for solubilizing intractable proteins, such as immunoglobulins and membrane components etc.
  • recombinant proteins expressed in an Escherichia coli system often face this problem of protein solubility. These proteins are frequently found in insoluble inclusion bodies and require solubilization by strong denaturant as the essential step to refold and generate the active conformation.
  • the current invention provides a process for the production of a correct folded protein or a salt thereof, characterized in that the protein is treated with a buffer comprising a denaturant, and the correct folded protein is separated therefrom directly, wherein the denaturant is selected from the group consisting of guanidine hydrochloride in a concentration from 3 to 7 M and urea in a concentration from 6 to 10 M.
  • the wording correct folded protein stands for a protein that is in the native conformation and/or shows a biological activity like the enzymatic activity or the binding property of the native protein.
  • the inventive process is applicable to any protein or protein fragment that has to be folded into a correct folded conformation and that establishes an equilibrium between a not correct and a correct folded conformation in presence of the denaturant. This is usually the case for proteins that are not irreversibly denatured by the denaturant.
  • the ability of a protein to establish said equilibrium can easily be monitored by standard methods that provide information on the folding of proteins in solution like NMR or circular dicroism.
  • the protein to be refolded by the inventive process may be from almost any source, a special pretreatment is not necessary but not excluded.
  • a recombinant protein that is stored in the producing host in form of inclusion bodies can be refolded by simply separating the inclusion bodies from the rest of the cell debris, solubilizing the proteins of the inclusion bodies with denaturant and isolating the correct folded protein therefrom.
  • the protein is not stored in form of inclusion bodies it is possible to enrich the protein only to some extend using, e.g., a precipitation step, solubilize the protein with the denaturant and isolate the pure and correct folded protein therefrom.
  • telomeres For recombinant proteins or natural proteins that are not in a correct folded conformation after isolation it is possible to solubilize these protein after isolation in the denaturant and isolate the correct folded fraction therefrom.
  • suitable proteins are hirudin, epidermal growth factor, potato carboxypeptidase inhibitor (PCI) and bovine pancreatic trypsin inhibitor (BPTI), IGF-1 , C5a- antagonist, TGF- ⁇ .
  • hirudin as used in this invention is intended to embrace all desulfatohirudin compounds described in literature or obtainable from a transformed microorganism strain containing DNA which codes for a desulfatohirudin or a derivative thereof.
  • Such hirudins are, for example, desulfatohirudin derivatives HV1 , HV2 and HV3 (PA), as well as other hirudin proteins as described e.g. by M. Scharf et al. (FEBS Lett., 255 (1989), 105-110) and EP-A-347376.
  • hirudin derivatives or shorter fragments having hirudin activity are also covered by the term "hirudin”.
  • Such fragments and derivatives are, for example, C-terminally shortened desulfatohirudins.
  • a and B represent percentages of native protein and scrambled species presented in equilibrium. A and B, both are smaller than 1 , can be readily derived from the equilibrium constant.
  • Another or additional possibility to shift the equilibrium towards the correct folded conformation is the addition of substances that promote correct folding like metal salts that stabilize the correct conformation or removing the native species using solid bound ligand that binds specifically to the native structure.
  • the correct folded and the not correct folded protein are separated continuously or discontinuously.
  • the concentration of guanidine hydrochloride is preferably from 4 to 6 M and the concentration of urea is preferably 7 to 9 M.
  • the process is carried out in presence of a reducing agent with a redoxpotential from -0.20 to -0.30 such as glutathione, cysteine or ⁇ -mercaptoethanol which is preferred.
  • concentration of the reducing agent is preferably from 0.05 to 1 mM and more preferably from 0.1 to 0.5 mM.
  • the denatu ration buffer or the buffer to that the correct folded protein is isolated may also contain additional compound that promote folding or prevent undesired side reactions.
  • additional compound that promote folding or prevent undesired side reactions.
  • further denaturants like SDS and Triton or metal ions, further reducing agents, oxidizing agents, complexing agents like EDTA or co-enzymes.
  • the correct folded protein may be separated from the not corrected folded protein by any process that is able to distinguish said two forms.
  • Said processes are, e.g., based on a difference in mobility, shape, reactivity or binding properties. Examples for suitable processes are antibody based, membrane based, electrophoretic or chromatographic separations like gel electrophoresis, gel filtration, thin layer chromatography (TLC), HPLC, affinity chromatography or separation via a selective membrane.
  • TLC thin layer chromatography
  • HPLC highLC
  • affinity chromatography affinity chromatography
  • the folding reactions is carried out preferably at a temperature that promotes the establishment of an equilibrium and does not irreversibly denature the protein. Therefore, the applied temperature mainly depends on the stability of the protein and the separation procedure for the correct folded protein. For example, certain proteins of thermophile microorganisms are stable at 60°C and above while proteins that originate from not thermophilic microorganisms might sometimes enter irreversible modifications at 40°C or below.
  • Fig. 1 is a HPLC protocol of the hirudin core domain (Hir 1" 9 ) in presence of 5 M guanidine hydrochloride and 0.25 mM ⁇ -mercaptoethanol.
  • Fig. 2 is a HPLC protocol of epidermal growth factor in presence of 3 M guanidine hydrochloride and 0.25 mM ⁇ -mercaptoethanol.
  • Example 1 Production and isolation of the hirudin core domain (Hir )
  • Recombinant desulfated hirudin was is isolated from Saccharomyces cerevisiae as described in Meyhack et al. (Thromb. Res. Suppl. VII (1987), 33).
  • the isolated desulfatohirudin is dissolved in 50 mM ammoniumbicarbonate buffer pH 8.0 at a concentration of 5 mg/ml and digested with chymotrypsin (0.25 mg/ml) at room temperature for 16 h. The digestion is terminated by addition of trif luoroacetic acid to a final concentration of 0.8 % and the core domain (Hir 1"49 ) is isolated by HPLC.
  • Solvent A 0.1 % trif luoroacetic acid in water
  • Solvent B 0.1 % trif luoroacetic acid in acetonitrile
  • the starting material for the folding experiments fully reduced / denatured core domain of hirudin [R], is prepared by the following method:
  • the hirudin core domain from examplel (2 mg/ml) is dissolved in Tris-HCI buffer (0.5 M, pH 8.5) containing 5 M of guanidine chloride (GdmCI) and 30 mM of dithiothreitol. Reduction and denaturation are carried out at 23°C for 90 min.
  • the sample is passed through a PD-IO* column (Pharmacia) equilibrated in 0.1 M Tris-HCI buffer (pH 8.5). Desalting takes about 1-2 min and the sample is immediately used in the folding experiments.
  • Example 3 Folding of hirudin in the presence of guanidine hydrochloride
  • the samples are diluted to a final protein concentration of 1 mg/ml; containing 0.1 M Tris- HCI buffer (pH 8.5), 5 M guanidine hydrochloride and 0.25 mM ⁇ -mercaptoethanol. After 24 h incubation at room temperature, the native hirudin is separated from scrambled hirudin via HPLC.
  • Solvent A 0.1 % trif luoroacetic acid in water
  • Solvent B 0.1 % trif luoroacetic acid in acetonitrile
  • HPLC-protocol is given in Figure 1.
  • the amount of native hirudin is calculated to 60% ⁇ 5 % and the K ⁇ to 0.67 ⁇ 0.15.
  • the traction containing the scrambled hirudin is lyophilized and dissolved in 0.1 M Tris-HCI buffer (pH 8.5) containing 5 M guanidine hydrochloride and 0.25 mM ⁇ -mercaptoethanol to a final protein concentration of 1 mg/ml. After 24 h incubation, the native hirudin is separated from scrambled hirudin via HPLC as described above Lyophilization and renaturation is carried out for a third time as described above.
  • the activity of the recovered hirudin is proved by the ability to inhibit human ⁇ -thrombin from digesting Chromozym (Boehringer Mannheim).
  • the reaction is carried at 22°C in 67 mM Tris-HCI buffer (pH 8.0) containing 133 mM NaCI and 0.13 % polyethylene glycol 6000.
  • the rate of digestion was followed at 405 nm for a period of 2 min.
  • the concentration of substrate is 200 mM.
  • the concentration of thrombin is adjusted in between 2.5 and 25 nM.
  • the recovered protein is carboxymethylated with 0.2 M iodoacetic acid in Tris-HCI buffer (0.5 M, pH 8.5) for 30 min and desalted through a PD-10 ® column equilibrated with ammonium bicarbonate solution (50 mM, pH 8.0).
  • the disulfide contents is determined by amino acid analysis (Chang and Knecht, Anal. Biochem. (1991), 197, 52-58) and mass spectrometry (Chatrenet and Chang, J. Biol. Chem. (1992), 267, 3038-3043).
  • the renaturation is carried out as described in example 3 with the sole difference that 8 M urea is used instead of 5 M guanidine hydrochloride.
  • the amount of native hirudin is calculated to 90 % ⁇ 5 % and the K ⁇ q to 0.11 ⁇ 0.06.
  • Epidermal growth factor is provided by Protein Institute Inc. (Broomall, USA) and is denatured as described for hirudin in example 2.
  • the renaturation is carried out as described in example 3 with the sole difference that EGF is used instead of hirudin and 3 M guanidine hydrochloride is used instead of 5 M guanidine hydrochloride.
  • the HPLC-protocol is given in Figure 2.
  • the disulfide content is determined as described in example3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a process for the preparation of a biologically active and correctly folded protein in the presence of a denaturing agent like urea or guanidine hydrochloride and the separation of the correctly folded protein therefrom directly. This process can be applied, for example, in the renaturation of recombinant proteins like hirudin or epidermal growth factor.

Description

Process for folding of proteins H e recomblnant h rudln or epidermal growth factor.
The invention relates to a process for the preparation of a biologically active and correctly folded protein in the presence of a denaturing agent.
Correct folding of genetically engineered proteins is a major issue in protein science. The problem is particularly acute, e.g., in the case of disulfide-containing proteins, which often need to be denatured and refolded to become active. Disulfide formation is an event of post-translational modification. It follows the pathway of protein folding and usually occurs faithfully in vivo. However, in the in vitro renaturation experiments, many proteins are recovered in poor yields and some do not fold into native conformation at all. To overcome this problem, a number of compounds, such as the mixture of reduced / oxidized gluta- thione (Creighton, Methods Enzymol. 131 (1986), 83-106) and protein disulfide isomerase (PDI) (Morin, J. E. & Dixon, J. E. Methods Enzymol. 113 (1985), 541-547) have been routinely used to promote the formation of disulfides. But despite their widespread use, the precise mechanism of their function remains undefined and their applications have been conducted in a manner of trial and error.
A number of publications have appeared which report refolding attempts for individual proteins produced in bacterial hosts, or which are otherwise in a denatured or non-native form. Formation of a dimeric, biologically active human colony stimulating factor-1 (CSF-1) after expression in E. coli is described in WO 88/8003 and by Halenbeck et al. Biotechnology, 7 (1989), 710-715. The procedures described involve the steps of initial solubilization of CSF-1 monomers isolated from inclusion bodies under reducing conditions in a chaotropic environment comprising urea or guanidine hydrochloride, refolding which is achieved by stepwise dilution of the chaotropic agents, and final oxidation of the refolded molecule in the presence of a redox-system. In WO 88/8849 a process for recovering recombinant interieukin-2 (IL-2) is disclosed, characterized in that IL-2 isolated from retractile bodies is denatured under reducing conditions with 6M guanidine hydrochloride, the soluble IL-2 is oxidized by a controlled oxidation in the presence of Cu2+ ions, and the oxidized IL-2 refolded by reducing the concentration of the denaturant in the solution. Interieukin-2 and interferon-β have been refolded using SDS for solubilization and Cu2+ ions as oxidation promoters of the fully reduced protein (US-A-4572798). The process for isolating recombinant retractile proteins as described in US-A-4620948 involves strong denaturing agents to solubilize the proteins, reducing conditions to facilitate correct folding and denaturant replacement in presence of air or other oxidizing agents to reform the disulfide bonds. A method for renaturing unfolded proteins including cytochrome c, ovalbumin and trypsin inhibitor by reversibly binding of the denatured protein to a solid matrix and stepwise renaturing it by diluting the denaturant is disclosed in WO 86/5809. The foregoing references are merely representative of a huge amount of literature dealing with the refolding of non-native proteins derived from different sources. The man skilled in the art on the other hand knows that the success of refolding experiments cannot be predicted. Unsuccessful experiments are usually not reported. There is no certainty that anyone of the reported refolding conditions would work at all with a given denatured protein containing several cysteine residues and therefore, a number of intramolecular disulfide bonds, which are required for activity.
Guanidine hydrochloride (GdmCI) and urea are the best known denaturants for unfolding and inactivating proteins. Although the mechanism of their actions remains to be fully understood, it is generally evident that they disrupt the non-covalent interactions which stabilize the native conformation. The detrimental effect of GdmCI and urea has also been illustrated during the folding of proteins, which usually leads to the formation of inactive, scrambled species (Haber and Anfinsen, J. Biol. Chem. (1962), 237, 1839-1844; Weissman and Kim Science (1991 ), 253, 1386-1393). On the other hand, denaturants are potent agents for solubilizing intractable proteins, such as immunoglobulins and membrane components etc. For example, recombinant proteins expressed in an Escherichia coli system often face this problem of protein solubility. These proteins are frequently found in insoluble inclusion bodies and require solubilization by strong denaturant as the essential step to refold and generate the active conformation.
Surprisingly it has now been found that in the presence of denaturant and under equilibrium conditions correct folded protein is formed and can be isolated therefrom directly. This finding greatly facilitate the preparation of recombinant proteins as these proteins can be solubilized using denaturing agents and isolated therefrom in their correct folded native conformation without removing the solubilizing denaturant. Additionally, the presence of - 3 -
high concentrations of denaturant usually inactivates proteases and makes an addition of protease inhibitors unnecessary.
Therefore, the current invention provides a process for the production of a correct folded protein or a salt thereof, characterized in that the protein is treated with a buffer comprising a denaturant, and the correct folded protein is separated therefrom directly, wherein the denaturant is selected from the group consisting of guanidine hydrochloride in a concentration from 3 to 7 M and urea in a concentration from 6 to 10 M.
The wording correct folded protein stands for a protein that is in the native conformation and/or shows a biological activity like the enzymatic activity or the binding property of the native protein.
The inventive process is applicable to any protein or protein fragment that has to be folded into a correct folded conformation and that establishes an equilibrium between a not correct and a correct folded conformation in presence of the denaturant. This is usually the case for proteins that are not irreversibly denatured by the denaturant. The ability of a protein to establish said equilibrium can easily be monitored by standard methods that provide information on the folding of proteins in solution like NMR or circular dicroism.
The protein to be refolded by the inventive process may be from almost any source, a special pretreatment is not necessary but not excluded. For example, a recombinant protein that is stored in the producing host in form of inclusion bodies can be refolded by simply separating the inclusion bodies from the rest of the cell debris, solubilizing the proteins of the inclusion bodies with denaturant and isolating the correct folded protein therefrom. In case the protein is not stored in form of inclusion bodies it is possible to enrich the protein only to some extend using, e.g., a precipitation step, solubilize the protein with the denaturant and isolate the pure and correct folded protein therefrom. For recombinant proteins or natural proteins that are not in a correct folded conformation after isolation it is possible to solubilize these protein after isolation in the denaturant and isolate the correct folded fraction therefrom. Examples for suitable proteins are hirudin, epidermal growth factor, potato carboxypeptidase inhibitor (PCI) and bovine pancreatic trypsin inhibitor (BPTI), IGF-1 , C5a- antagonist, TGF-β. Especially preferred proteins are hirudin and epidermal growth factor (EGF).
The term "hirudin" as used in this invention is intended to embrace all desulfatohirudin compounds described in literature or obtainable from a transformed microorganism strain containing DNA which codes for a desulfatohirudin or a derivative thereof. Such hirudins are, for example, desulfatohirudin derivatives HV1 , HV2 and HV3 (PA), as well as other hirudin proteins as described e.g. by M. Scharf et al. (FEBS Lett., 255 (1989), 105-110) and EP-A-347376. It is to be understood that hirudin derivatives or shorter fragments having hirudin activity are also covered by the term "hirudin". Such fragments and derivatives are, for example, C-terminally shortened desulfatohirudins.
Since not correct folded (scrambled) species and correct folded (native) protein exist in equilibrium under denaturant, one may design conditions to tip the equilibrium in favor of the native conformation. One possible approach is to remove the native species continuously during the folding. Another strategy is simply to recycle the scrambled species. This can be achieved by isolating the scrambled species and allowing them to re- equilibrate in the denaturant in order to generate the native protein. Knowing the equilibrium constant under selected denaturing conditions, one can calculate the total yield of native protein using the following formula,
Yield = A . ( 1 + B + B2 + ... + Bn )
where n represents the times of recycling, A and B represent percentages of native protein and scrambled species presented in equilibrium. A and B, both are smaller than 1 , can be readily derived from the equilibrium constant.
Another or additional possibility to shift the equilibrium towards the correct folded conformation is the addition of substances that promote correct folding like metal salts that stabilize the correct conformation or removing the native species using solid bound ligand that binds specifically to the native structure. In a preferred embodiment of the invention, the correct folded and the not correct folded protein are separated continuously or discontinuously.
All denaturants that allow the solubilized protein to establish an equilibrium between not correct folded and correct folded conformation can be used in the process according to the invention.
The concentration of guanidine hydrochloride is preferably from 4 to 6 M and the concentration of urea is preferably 7 to 9 M.
If the protein to be folded comprises in the correct folded conformation one or more disulfide bonds the addition of a reducing agent or a redox system is recommended. Advantageously, the process is carried out in presence of a reducing agent with a redoxpotential from -0.20 to -0.30 such as glutathione, cysteine or β-mercaptoethanol which is preferred. The concentration of the reducing agent is preferably from 0.05 to 1 mM and more preferably from 0.1 to 0.5 mM.
The denatu ration buffer or the buffer to that the correct folded protein is isolated may also contain additional compound that promote folding or prevent undesired side reactions. Examples are further denaturants like SDS and Triton or metal ions, further reducing agents, oxidizing agents, complexing agents like EDTA or co-enzymes.
The correct folded protein may be separated from the not corrected folded protein by any process that is able to distinguish said two forms. Said processes are, e.g., based on a difference in mobility, shape, reactivity or binding properties. Examples for suitable processes are antibody based, membrane based, electrophoretic or chromatographic separations like gel electrophoresis, gel filtration, thin layer chromatography (TLC), HPLC, affinity chromatography or separation via a selective membrane. In a preferred embodiment of the invention the correct folded protein is separated by HPLC, TLC or affinity chromatography. In case the correct folded protein is separated discontinuously the conditions that are necessary to establish said equilibrium have to be adapted again, e.g., by concentration or dilution of the remaining solution. It is for example possible to isolate the correct and the not-correct folded protein separately, e.g. with a HPLC column, concentrate the fraction containing the not correct folded protein and solubilize it once more under denaturating conditions. If the separation process is carried out continuously the concentrations of the essential components can be monitored, e.g. using spectroscopic means, and continuously adapted.
The folding reactions is carried out preferably at a temperature that promotes the establishment of an equilibrium and does not irreversibly denature the protein. Therefore, the applied temperature mainly depends on the stability of the protein and the separation procedure for the correct folded protein. For example, certain proteins of thermophile microorganisms are stable at 60°C and above while proteins that originate from not thermophilic microorganisms might sometimes enter irreversible modifications at 40°C or below.
Brief description of the drawings
In the following experimental part various embodiments of the present invention are described with reference to the accompanying drawings in which:
Fig. 1 is a HPLC protocol of the hirudin core domain (Hir1" 9) in presence of 5 M guanidine hydrochloride and 0.25 mM β-mercaptoethanol. Fig. 2 is a HPLC protocol of epidermal growth factor in presence of 3 M guanidine hydrochloride and 0.25 mM β-mercaptoethanol. EXPERIMENTAL PROCEDURES
Example 1 : Production and isolation of the hirudin core domain (Hir )
Recombinant desulfated hirudin was is isolated from Saccharomyces cerevisiae as described in Meyhack et al. (Thromb. Res. Suppl. VII (1987), 33). The isolated desulfatohirudin is dissolved in 50 mM ammoniumbicarbonate buffer pH 8.0 at a concentration of 5 mg/ml and digested with chymotrypsin (0.25 mg/ml) at room temperature for 16 h. The digestion is terminated by addition of trif luoroacetic acid to a final concentration of 0.8 % and the core domain (Hir1"49) is isolated by HPLC.
Condition for HPLC:
Column: Vydac C-18
Solvent A: 0.1 % trif luoroacetic acid in water
Solvent B: 0.1 % trif luoroacetic acid in acetonitrile
Gradient: 10 % B to 48 % B in 30 min at 23°C
Retention time for Hir1"49: 14.3 min
Example 2: Denaturation of the hirudin core domain (Hir )
The starting material for the folding experiments, fully reduced / denatured core domain of hirudin [R], is prepared by the following method:
The hirudin core domain from examplel (2 mg/ml) is dissolved in Tris-HCI buffer (0.5 M, pH 8.5) containing 5 M of guanidine chloride (GdmCI) and 30 mM of dithiothreitol. Reduction and denaturation are carried out at 23°C for 90 min. To initiate the folding, the sample is passed through a PD-IO* column (Pharmacia) equilibrated in 0.1 M Tris-HCI buffer (pH 8.5). Desalting takes about 1-2 min and the sample is immediately used in the folding experiments. Example 3: Folding of hirudin in the presence of guanidine hydrochloride
The samples are diluted to a final protein concentration of 1 mg/ml; containing 0.1 M Tris- HCI buffer (pH 8.5), 5 M guanidine hydrochloride and 0.25 mM β-mercaptoethanol. After 24 h incubation at room temperature, the native hirudin is separated from scrambled hirudin via HPLC.
Condition for HPLC:
Column: Vydac C-18
Solvent A: 0.1 % trif luoroacetic acid in water
Solvent B: 0.1 % trif luoroacetic acid in acetonitrile
Gradient: 14 % B to 32 % B in 50 min at 23°C
Retention time for Hir1"49: 23 min
The HPLC-protocol is given in Figure 1.
From the integration of the HPLC-protocol values the amount of native hirudin is calculated to 60% ± 5 % and the K^ to 0.67 ± 0.15.
The traction containing the scrambled hirudin is lyophilized and dissolved in 0.1 M Tris-HCI buffer (pH 8.5) containing 5 M guanidine hydrochloride and 0.25 mM β-mercaptoethanol to a final protein concentration of 1 mg/ml. After 24 h incubation, the native hirudin is separated from scrambled hirudin via HPLC as described above Lyophilization and renaturation is carried out for a third time as described above.
All fractions containing the native hirudin are combined and the total recovery of native hirudin sums up to 97 % after three cycles.
The activity of the recovered hirudin is proved by the ability to inhibit human α-thrombin from digesting Chromozym (Boehringer Mannheim). The reaction is carried at 22°C in 67 mM Tris-HCI buffer (pH 8.0) containing 133 mM NaCI and 0.13 % polyethylene glycol 6000. The rate of digestion was followed at 405 nm for a period of 2 min. The concentration of substrate is 200 mM. The concentration of thrombin is adjusted in between 2.5 and 25 nM.
For further structural analysis the recovered protein is carboxymethylated with 0.2 M iodoacetic acid in Tris-HCI buffer (0.5 M, pH 8.5) for 30 min and desalted through a PD-10® column equilibrated with ammonium bicarbonate solution (50 mM, pH 8.0). The disulfide contents is determined by amino acid analysis (Chang and Knecht, Anal. Biochem. (1991), 197, 52-58) and mass spectrometry (Chatrenet and Chang, J. Biol. Chem. (1992), 267, 3038-3043).
Example 4: Folding of hirudin in the presence of urea
The renaturation is carried out as described in example 3 with the sole difference that 8 M urea is used instead of 5 M guanidine hydrochloride.
From the integration of the HPLC-protocol values the amount of native hirudin is calculated to 90 % ± 5 % and the Kβq to 0.11 ± 0.06.
After two cycles, the total recovery of native hirudin is 99 %.
Example 5: Denaturation of epidermal growth factor
Epidermal growth factor (EGF) is provided by Protein Institute Inc. (Broomall, USA) and is denatured as described for hirudin in example 2.
Example 6: Folding of EGF in the presence of guanidine hydrochloride
The renaturation is carried out as described in example 3 with the sole difference that EGF is used instead of hirudin and 3 M guanidine hydrochloride is used instead of 5 M guanidine hydrochloride. The HPLC-protocol is given in Figure 2.
From the integration of the HPLC-protocol values the amount of native EGF is calculated to 89% ± 5 % and the Kβq to 0.12 ± 0.07.
After two cycles, the total recovery of native EGF is 99%.
The disulfide content is determined as described in example3.

Claims

- 1 1 -Claims:
1. A process for the production of a correct folded protein or a salt thereof, characterized in that the protein is treated with a buffer comprising a denaturant, and the correct folded protein is separated therefrom directly, wherein the denaturant is selected from the group consisting of guanidine hydrochloride in a concentration from 3 to 7 M and urea in a concentration from 6 to 10 M.
2. A process according to claim 1 , wherein the correct folded protein is separated continuously or discontinuously.
3. A process according to claim 1 , wherein the correct folded protein is separated discontinuously.
4. A process according to claim 1 , wherein the protein is hirudin or epidermal growth factor.
5. A process according to claim 1 , wherein the concentration of guanidine hydrochloride is from 4 to 6 M.
6. A process according to claim 1. wherein the concentration of urea is 7 to 9 M.
7. A process according to claim 1 , wherein a reducing agent is present.
8. A process according to claim 7, wherein the reducing agent has a redoxpotential from - 0.20 to -0.30.
9. A process according to claim 7, wherein the reducing agent is β-mercaptoethanol.
10. A process according to claim 7, wherein the concentration of the reducing agent is from 0.05 to 1 mM.
11.A process according to claim 7, wherein the concentration of the reducing agent is from 0.1 to 0.5 mM.
12. A process according to claim 1 , wherein the correct folded protein is separated by antibody based, membrane based, electrophoretic or chromatographic separations.
13. A process according to claim 1 , wherein the correct folded protein is separated by HPLC, TLC or affinity chromatography.
PCT/EP1995/002720 1994-07-25 1995-07-12 Process for folding of proteins like recombinant hirudin or epidermal growth factor WO1996003425A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU31097/95A AU3109795A (en) 1994-07-25 1995-07-12 Process for folding of proteins like recombinant hirudin or epidermal growth factor
JP8505402A JPH11505507A (en) 1994-07-25 1995-07-12 Methods for folding proteins such as recombinant hirudin or epidermal growth factor
MX9700658A MX9700658A (en) 1995-07-12 1995-07-12 Process for folding of proteins like recombinant hirudin or epidermal growth factor.
EP95926859A EP0804461A1 (en) 1994-07-25 1995-07-12 Process for folding of proteins like recombinant hirudin or epidermal growth factor
NO970081A NO970081D0 (en) 1994-07-25 1997-01-09 Method of folding proteins such as recombinant hirudin or epidermal growth factor
FI970230A FI970230A0 (en) 1994-07-25 1997-01-20 Method for folding proteins such as recombinant hirudin or epidermal growth factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810437 1994-07-25
EP94810437.7 1994-07-25

Publications (1)

Publication Number Publication Date
WO1996003425A1 true WO1996003425A1 (en) 1996-02-08

Family

ID=8218291

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002720 WO1996003425A1 (en) 1994-07-25 1995-07-12 Process for folding of proteins like recombinant hirudin or epidermal growth factor

Country Status (9)

Country Link
EP (1) EP0804461A1 (en)
JP (1) JPH11505507A (en)
AU (1) AU3109795A (en)
CA (1) CA2194177A1 (en)
FI (1) FI970230A0 (en)
IL (1) IL114699A0 (en)
NO (1) NO970081D0 (en)
WO (1) WO1996003425A1 (en)
ZA (1) ZA956137B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1035129A1 (en) * 1999-03-03 2000-09-13 Higeta Shoyu Co., Ltd. A method of activating protein and an apparatus therefor
WO2003097669A2 (en) * 2002-05-17 2003-11-27 Københavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
US7521479B2 (en) 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114506A1 (en) * 1982-12-22 1984-08-01 Genentech, Inc. Methods of purification and reactivation of precipitated heterologous proteins
EP0192629A2 (en) * 1985-02-22 1986-08-27 Monsanto Company Method of somatotropin solubilization and naturation
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
EP0529086A1 (en) * 1991-02-26 1993-03-03 Ajinomoto Co., Inc. Processes for purifying human bcdf
WO1993021224A1 (en) * 1992-04-16 1993-10-28 Allelix Biopharmaceuticals Inc. Ultrapure human epidermal growth factor

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114506A1 (en) * 1982-12-22 1984-08-01 Genentech, Inc. Methods of purification and reactivation of precipitated heterologous proteins
EP0192629A2 (en) * 1985-02-22 1986-08-27 Monsanto Company Method of somatotropin solubilization and naturation
EP0433225A1 (en) * 1989-12-06 1991-06-19 Ciba-Geigy Ag Process for the production of biologically active protein (e.g. TGF)
EP0529086A1 (en) * 1991-02-26 1993-03-03 Ajinomoto Co., Inc. Processes for purifying human bcdf
WO1993021224A1 (en) * 1992-04-16 1993-10-28 Allelix Biopharmaceuticals Inc. Ultrapure human epidermal growth factor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. CHATRENET AND J.-Y. CHANG: "The Folding of Hirudin Adopts a Mechanism of Trial and Error", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 5, 15 February 1992 (1992-02-15), BALTIMORE, MD US, pages 3038 - 3043 *
L.O. NARHI ET AL.: "Circular dichroism of reduced and oxidized recombinant human epidermal growth factor", INTERNATIONAL JOURNAL OF PEPTIDE AND PROTEIN RESEARCH, vol. 39, no. 2, COPENHAGEN DK, pages 182 - 187 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1035129A1 (en) * 1999-03-03 2000-09-13 Higeta Shoyu Co., Ltd. A method of activating protein and an apparatus therefor
US6479257B1 (en) 1999-03-03 2002-11-12 Higeta Shoyu Co., Ltd. Method of activating protein and an apparatus therefor
US7521479B2 (en) 2001-04-16 2009-04-21 Panacea Pharmaceuticals, Inc. Methods of treating prion disease in mammals
WO2003097669A2 (en) * 2002-05-17 2003-11-27 Københavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
WO2003097669A3 (en) * 2002-05-17 2004-03-18 Univ Koebenhavn Method for purifying denatured proteins having a desired disulfide bond configuration

Also Published As

Publication number Publication date
ZA956137B (en) 1996-03-07
FI970230A (en) 1997-01-20
NO970081L (en) 1997-01-09
JPH11505507A (en) 1999-05-21
NO970081D0 (en) 1997-01-09
AU3109795A (en) 1996-02-22
CA2194177A1 (en) 1996-02-08
EP0804461A1 (en) 1997-11-05
IL114699A0 (en) 1995-11-27
FI970230A0 (en) 1997-01-20

Similar Documents

Publication Publication Date Title
Rudolph et al. In vitro folding of inclusion body proteins
Clark Refolding of recombinant proteins
Fischer et al. Isolation, renaturation, and formation of disulfide bonds of eukaryotic proteins expressed in Escherichia coli as inclusion bodies
Singh et al. Solubilization and refolding of bacterial inclusion body proteins
US20050239162A1 (en) Process for folding chemically synthesized polypeptides
WO1999038984A1 (en) Process for producing peptide with the use of accessory peptide
EA020621B1 (en) Refolding proteins using a chemically controlled redox state
CA1340877C (en) Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
Wei et al. Oxidative refolding of recombinant prochymosin
Ruoppolo et al. Refolding by disulfide isomerization: the mixed disulfide between ribonuclease T1 and glutathione as a model refolding substrate
US20140323687A1 (en) Method for protein isolation in anoxic conditions
EP0804461A1 (en) Process for folding of proteins like recombinant hirudin or epidermal growth factor
JP3070935B2 (en) A method for biocatalytic accurate chain folding of denatured recombinant fusion proteins
US4960868A (en) Method of cleavage at methionine of polypeptides
Leong et al. Dilution versus dialysis: a quantitative study of the oxidative refolding of recombinant human alpha-fetoprotein
KR100327040B1 (en) Process for the preparation of active somatotropin from inclusion bodies
CA2160663A1 (en) A method of detecting the presence of and converting of a polypeptide
MXPA97000658A (en) Process for the folding of proteins as recombinant hirudine or growth factor epiderm
EP1453858A1 (en) Process for renaturation of recombinant, disulfide containing proteins at high protein concentrations in the presence of amines
Chang Quantitative analysis of the composition of the native and scrambled ribonuclease A
EP0037256A1 (en) Process for producing an insulin
EP0649856A1 (en) Process for the production of correct folded protein
Kim et al. Enhanced in vitro refolding selectivity of the recombinant human insulin-like growth factor I
US20070042460A1 (en) Oxidation of peptides
US20060252917A1 (en) Methods for refolding conformationally constrained peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995926859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2194177

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 970230

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 1996 505402

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 1997 776441

Country of ref document: US

Date of ref document: 19970124

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/000658

Country of ref document: MX

Ref document number: 1019970700473

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1019970700473

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1995926859

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995926859

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970700473

Country of ref document: KR